It has become recognized that tests for the development of a vaccine to eradicate the pandemic "Covid-19" are a complex process that requires time and funding .. With the concerted international efforts around the world after the number of infections around the world exceeded the barrier of 6 million infections, and 369,544 deaths to date ... The interface: 5 competing companies carrying the possible vaccine that reached promising results with recovery, and they are certain that its supply needs time that may extend from September to the end of the year.

Moderna Moderna

Moderna mRNA-1273 vaccine is the first vaccine to enter the clinical trial phase, just eight weeks after the publication of the "Covid-19" genetic sequence in January.

The American Biotechnology Company said that the interim data from the first stage experiment, which included 45 people, found that it produced antibodies to "Covid-19" in all participants at similar levels or higher who were infected with the virus, including in low doses.

Read also: After recovery from "Covid-19" ... Here are answers to the most common questions

Initial results showed that the vaccine provides protection against viral reproduction in the lungs.

Cancinoa CanSino

Chinese CanSino Biologics has become the first competitor to transfer its candidate vaccine - Ad5-nCoV - to the second stage of clinical trials taking place in Wuhan, however, the company has not published detailed results for the trial of the first stage, saying only that it is moving to the second stage based on "data" Primary Safety "from the first stage, in which about 500 people participated.

University of Oxford Oxford University

The University's ChAdOx1 nCoV-19 vaccine is being tested in more than 1,000 volunteers between the ages of 18 and 55 in the first stage trial that started last month.

A research paper that has not been reviewed yet on the effectiveness of the vaccine in monkeys, found that the vaccine prevented them from infection with pneumonia, which causes death in the virus, but it did not protect them from infection, which creates fears that if it is used in humans, this means that it will not be able to prevent Transmission of the virus to others.

The results of the human experiment could be available this month, and AstraZeneca, a Cambridge-based drug group, collaborated with Oxford University to manufacture and distribute the vaccine if the trials showed it was effective.

Imperial College London Imperial College London

Imperial is developing a vaccine in a form that has not been previously tested in humans. The team, led by Professor Robin Shattuck, has been testing animals since early February and human trials are due to start in June.

The company initially received 22.5 million pounds of government funding, and received an additional 18.5 million pounds which it hopes will enable it to launch the third phase of clinical trials later this year.

However, Shattuck warned that the vaccine was unlikely to be available for use in the UK by September.

Innovio Inovio

American biotechnology company Inovio, which has been in existence for four decades, has not been able to develop an approved product, but its stock has risen after it began its experiment last month, and says its candidate INO-4800 vaccine has led to promising immune responses in preclinical models.

The company has registered 40 healthy people in its first-stage experience, and hopes to advance to the second and third stage of the event's experiences this summer.

The company received a total of $ 17.2 million (£ 14 million) in grants for innovative epidemiological preparations for the vaccine.